Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference

Authors

Miloš Milovančević (ORCID: https://orcid.org/0000-0002-7891-1010)
Klaus Groes Larsen (ORCID: https://orcid.org/0000-0002-5990-0113)
Nanco Hefting
Caroline Ward (ORCID: https://orcid.org/0000-0001-8362-4713)
Eva Kohegyi (ORCID: https://orcid.org/0000-0003-1480-1362)
Dalei Chen
C. Aurang
Christoph U Correll
Mary Hobart

Institutions

Lundbeck (Denmark) (DK)
University of Belgrade (RS)
Otsuka (United States) (US)
Institute of Mental Health (RS)

Publication Details

Journal: The Lancet Psychiatry
Published: 2025-04-08
DOI: https://doi.org/10.1016/s2215-0366(25)00043-4
Citations: 7
Primary Topic: Schizophrenia research and treatment
Type: article
Field-Weighted Citation Impact: 10.30

Funders

H. Lundbeck A/S
Otsuka Pharmaceutical Development and Commercialization

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference

Miloš Milovančević, Klaus Groes Larsen, Nanco Hefting, Caroline Ward et al.

Apr 8, 2025

7 citations

The Lancet Psychiatry

Schizophrenia research and treatment

10.30

article

Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference

Miloš Milovančević, Klaus Groes Larsen, Nanco Hefting, Caroline Ward, Eva Kohegyi, Dalei Chen, C. Aurang, Christoph U Correll, Mary Hobart

April 8, 2025article en

7 citations

Abstract

No abstract available for this paper.

The Lancet PsychiatryVol. 12(5)

Lundbeck (Denmark) (DK), University of Belgrade (RS), Otsuka (United States) (US), Institute of Mental Health (RS)

H. Lundbeck A/S, Otsuka Pharmaceutical Development and Commercialization

Good health and well-being

Openalex Percentile: Top 2%

Schizophrenia research and treatment

10.30

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.